202 related articles for article (PubMed ID: 31635093)
1. Diagnostic and Prognostic Value of
Picardo F; Romanelli A; Muinelo-Romay L; Mazza T; Fusilli C; Parrella P; Barbazán J; Lopez-López R; Barbano R; De Robertis M; Taffon C; Bordoni V; Agrati C; Costantini M; Ricci F; Graziano P; Maiello E; Muscarella LA; Fazio VM; Poeta ML
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635093
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors.
Poeta ML; Massi E; Parrella P; Pellegrini P; De Robertis M; Copetti M; Rabitti C; Perrone G; Muda AO; Molinari F; Zanellato E; Crippa S; Caputo D; Caricato M; Frattini M; Coppola R; Fazio VM
Genes Chromosomes Cancer; 2012 Dec; 51(12):1133-43. PubMed ID: 22927297
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylated
Lukacova E; Burjanivova T; Podlesniy P; Grendar M; Turyova E; Kasubova I; Laca L; Mikolajcik P; Kudelova E; Vanochova A; Miklusica J; Mersakova S; Lasabova Z
Front Oncol; 2023; 13():1205791. PubMed ID: 37476382
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
5. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.
Haldrup C; Pedersen AL; Øgaard N; Strand SH; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Mol Oncol; 2018 Apr; 12(4):545-560. PubMed ID: 29465788
[TBL] [Abstract][Full Text] [Related]
6. SCTR hypermethylation is a diagnostic biomarker in colorectal cancer.
Li D; Zhang L; Fu J; Huang H; Sun S; Zhang D; Zhao L; Ucheojor Onwuka J; Zhao Y; Cui B
Cancer Sci; 2020 Dec; 111(12):4558-4566. PubMed ID: 32970347
[TBL] [Abstract][Full Text] [Related]
7. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
8. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
11. Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method.
Rezvani N; Alibakhshi R; Vaisi-Raygani A; Bashiri H; Saidijam M
Oncol Lett; 2017 May; 13(5):3277-3284. PubMed ID: 28521434
[TBL] [Abstract][Full Text] [Related]
12. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
13. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA.
Han YD; Oh TJ; Chung TH; Jang HW; Kim YN; An S; Kim NK
Clin Epigenetics; 2019 Mar; 11(1):51. PubMed ID: 30876480
[TBL] [Abstract][Full Text] [Related]
14. Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker.
Behrouz Sharif S; Hashemzadeh S; Mousavi Ardehaie R; Eftekharsadat A; Ghojazadeh M; Mehrtash AH; Estiar MA; Teimoori-Toolabi L; Sakhinia E
Oncol Lett; 2016 Dec; 12(6):5335-5343. PubMed ID: 28105243
[TBL] [Abstract][Full Text] [Related]
15. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
16. The role of
Hu H; Chen X; Wang C; Jiang Y; Li J; Ying X; Yang Y; Li B; Zhou C; Zhong J; Wu D; Ying J; Duan S
Oncotarget; 2017 Oct; 8(48):84054-84065. PubMed ID: 29137404
[TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
18. Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis.
Chen L; Lu D; Sun K; Xu Y; Hu P; Li X; Xu F
Gene; 2019 Apr; 692():119-125. PubMed ID: 30654001
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection.
Rasmussen SL; Krarup HB; Sunesen KG; Johansen MB; Stender MT; Pedersen IS; Madsen PH; Thorlacius-Ussing O
PLoS One; 2017; 12(7):e0180809. PubMed ID: 28700744
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer.
Kou CH; Zhou T; Han XL; Zhuang HJ; Qian HX
Oncol Lett; 2016 Dec; 12(6):4838-4844. PubMed ID: 28101227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
